Lincoln Pharmaceuticals Reports FY26 Growth, Recommends 18% Dividend

Lincoln Pharmaceuticals reported a total income of ₹704.48 crore for the financial year ended March 31, 2026, a rise from ₹645.71 crore in FY25. Net profit for the same period stood at ₹87.89 crore, up from ₹82.35 crore in the previous fiscal year.

Reader Takeaway: Steady annual growth and dividend payout, but global headwinds impacted Q4.

What just happened

Lincoln Pharmaceuticals released its audited standalone financial results for the fourth quarter and full financial year 2025-26. The company announced a total income of ₹704.48 crore for FY26, compared to ₹645.71 crore in FY25. Net profit increased to ₹87.89 crore in FY26 from ₹82.35 crore in FY25. For the fourth quarter ended March 31, 2026, total income was ₹183.08 crore and net profit was ₹11.63 crore. The Board recommended a dividend of 18%, or ₹1.80 per share, for the fiscal year 2025-26.

Why this matters

The results indicate a year-on-year growth in revenue and profitability for Lincoln Pharmaceuticals. The recommended dividend provides a direct return to shareholders. Furthermore, the company's forward-looking statement about achieving ₹1,000 crore in revenue within three years signals its growth ambitions.

The backstory

Lincoln Pharmaceuticals is a pharmaceutical company with a focus on both domestic and international markets. The company has been working on expanding its product portfolio and global footprint. Recent financial periods have seen the company navigate various market conditions, including supply chain disruptions and evolving regulatory landscapes.

What changes now

Investors will be looking for the company to execute its growth strategy, including expanding its export reach to 90 countries and achieving 15-18% annual growth. The recommended dividend will require shareholder approval at the upcoming AGM. The company also highlighted that its Q4 FY26 performance was affected by global war and economic scenarios, a factor that will be crucial to monitor.

Risks to watch

Management pointed to macroeconomic headwinds, specifically global war and economic scenarios, as impacting the Q4 performance. Additionally, ongoing challenges related to working-capital intensity, regulatory hurdles, and competitive pressures remain areas of focus for the company.

Peer comparison

(Information not available in the filing)

Context metrics (time-bound)

• FY26 Total Income: ₹704.48 crore (vs. ₹645.71 crore in FY25)
• FY26 Net Profit: ₹87.89 crore (vs. ₹82.35 crore in FY25)
• Dividend Recommendation: 18% (₹1.80 per share)
• Revenue Target: ₹1,000 crore in 3 years

What to track next

Investors should track the company's progress towards its ₹1,000 crore revenue target, its expansion into new export markets, and its ability to manage working-capital intensity and navigate global economic uncertainties.